文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

重度室间隔肥厚患者酒精室间隔消融术的长期结局

Alcohol septal ablation in patients with severe septal hypertrophy.
PubMed 文献 · Heart · 2019-08-30

基于Euro-ASA注册研究,比较室间隔基底段厚度≥30 mm与<30 mm的梗阻性肥厚型心肌病患者接受酒精室间隔消融术的短期和长期结局。两组短期主要不良事件相似,长期呼吸困难缓解、残余左室流出道梗阻及再次室间隔减容术也无差异,但≥30 mm组长期全因死亡率和心源性死亡率更差。

要点

  • 重度室间隔肥厚(≥30 mm)患者酒精室间隔消融术后短期结局与室间隔厚度<30 mm者相似。
  • 长期呼吸困难缓解、残余流出道梗阻及再次室间隔减容术在两组间无差异。
  • 室间隔厚度≥30 mm者长期全因死亡率和心源性死亡率更差。

核心结论

  • 室间隔基底段厚度≥30 mm的患者接受酒精室间隔消融术后短期结果及长期症状缓解、残余梗阻和再次减容术与<30 mm者相似,但长期全因和心源性死亡率更差。

研究设计与样本

  • 基于Euro-ASA注册研究,比较九个欧洲中心接受酒精室间隔消融术的梗阻性肥厚型心肌病患者,按室间隔基底段厚度<30 mm与≥30 mm分组。
  • 共纳入1519例有症状的梗阻性肥厚型心肌病患者(57±14岁,49%女性),其中67例(4.4%)室间隔厚度≥30 mm。

主要发现

  • 短期主要不良事件发生率在两组间相似。
  • 平均随访分别为5.4±4.3年和5.1±4.1年,全因死亡率在室间隔<30 mm组和≥30 mm组分别为每100人年2.57和2.94例死亡(p=0.047)。
  • 呼吸困难(NYHA III/IV级12% vs 16%)、残余左室流出道压差(16±20 vs 16±16 mm Hg)和再次室间隔减容术(12% vs 18%)在室间隔<30 mm组和≥30 mm组间均无差异(p=NS)。

临床怎么用

  • 对于室间隔基底段厚度≥30 mm的梗阻性肥厚型心肌病患者,酒精室间隔消融术可考虑用于缓解症状和流出道梗阻,但需关注长期死亡风险可能更高。

局限性

  • 室间隔厚度≥30 mm的患者样本量较小(67例,占4.4%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The current guidelines suggest alcohol septal ablation (ASA) is less effective in hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular hypertrophy, despite acknowledging that systematic data are lacking. Therefore, we analysed patients in the Euro-ASA registry to test this statement. METHODS: We compared the short-term and long-term outcomes of patients with basal interventricular septum (IVS) thickness <30 mm Hg to those with ≥30 mm Hg treated using ASA in nine European centres. RESULTS: A total of 1519 patients (57±14 years, 49% women) with symptomatic HOCM were treated, including 67 (4.4%) patients with IVS thickness ≥30 mm. The occurrence of short-term major adverse events were similar in both groups. The mean follow-up was 5.4±4.3 years and 5.1±4.1 years, and the all-cause mortality rate was 2.57 and 2.94 deaths per 100 person-years of follow-up in the IVS <30 mm group and the IVS ≥30 mm group (p=0.047), respectively. There were no differences in dyspnoea (New York Heart Association class III/IV 12% vs 16%), residual left ventricular outflow tract gradient (16±20 vs 16±16 mm Hg) and repeated septal reduction procedures (12% vs 18%) in the IVS <30 mm group and IVS ≥30 mm group, respectively (p=NS for all). CONCLUSIONS: The short-term results and the long-term relief of dyspnoea, residual left ventricular outflow obstruction and occurrence of repeated septal reduction procedures in patients with basal IVS ≥30 mm is similar to those with IVS <30mm. However, long-term all-cause and cardiac mortality rates are worse in the ≥30 mm group.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Veselka J, Jensen M, Liebregts M, et al. Alcohol septal ablation in patients with severe septal hypertrophy. Heart. 2019. PMID: 31471463. doi:10.1136/heartjnl-2019-315422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。